Chemical & Engineering News: Latest News

BMS-owned RayzeBio licenses Philochem asset for $350 million up front

RayzeBio gets global rights to radiopharmaceutical OncoACP3, which targets prostate cancer

Jun 12, 2025 - 18:35
 0
BMS-owned RayzeBio licenses Philochem asset for $350 million up front
RayzeBio gets global rights to radiopharmaceutical OncoACP3, which targets prostate cancer
Read More

Tags:

Previous Article

Klarna Partners With Nift, Offering Gifts Throughout Purchase Cycle to Customers

Next Article

BioNTech to buy fellow German mRNA firm CureVac

Related Posts

Congressional hearing confronts contentious deep-sea mining issues

Congressional hearing confronts contentious deep-sea mi...

May 18, 2025  0

More hurt for European chemical firms

More hurt for European chemical firms

May 12, 2025  0

AI start-up raises $11 million to make drug formulations better

AI start-up raises $11 million to make drug formulation...

May 16, 2025  0